SG Americas Securities LLC Buys Shares of 45,426 Syndax Pharmaceuticals, Inc. $SNDX

SG Americas Securities LLC bought a new position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 45,426 shares of the company’s stock, valued at approximately $699,000.

Several other institutional investors have also recently modified their holdings of SNDX. AQR Capital Management LLC increased its holdings in shares of Syndax Pharmaceuticals by 478.8% during the 1st quarter. AQR Capital Management LLC now owns 377,444 shares of the company’s stock valued at $4,637,000 after purchasing an additional 312,231 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Syndax Pharmaceuticals by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,842 shares of the company’s stock valued at $705,000 after buying an additional 3,094 shares in the last quarter. Caxton Associates LLP acquired a new stake in Syndax Pharmaceuticals during the first quarter worth about $257,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Syndax Pharmaceuticals by 18.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 200,696 shares of the company’s stock valued at $2,466,000 after buying an additional 30,596 shares during the period. Finally, Aberdeen Group plc grew its holdings in shares of Syndax Pharmaceuticals by 129.1% during the 2nd quarter. Aberdeen Group plc now owns 303,426 shares of the company’s stock worth $2,842,000 after purchasing an additional 170,993 shares during the period.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Syndax Pharmaceuticals in a research report on Monday, October 27th. Barclays increased their target price on shares of Syndax Pharmaceuticals from $22.00 to $35.00 and gave the company an “overweight” rating in a research report on Monday, November 24th. Wall Street Zen cut Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, January 11th. UBS Group boosted their price target on Syndax Pharmaceuticals from $35.00 to $38.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Finally, BTIG Research reiterated a “buy” rating and set a $56.00 target price on shares of Syndax Pharmaceuticals in a research report on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Syndax Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $37.20.

Syndax Pharmaceuticals Trading Up 1.4%

NASDAQ:SNDX opened at $20.52 on Thursday. The company has a market capitalization of $1.78 billion, a PE ratio of -5.68 and a beta of 0.48. The company has a quick ratio of 4.42, a current ratio of 4.64 and a debt-to-equity ratio of 2.78. Syndax Pharmaceuticals, Inc. has a 52-week low of $8.58 and a 52-week high of $22.73. The stock has a fifty day simple moving average of $20.04 and a 200-day simple moving average of $16.07.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its earnings results on Monday, November 3rd. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.04. The firm had revenue of $45.87 million during the quarter, compared to the consensus estimate of $49.08 million. Syndax Pharmaceuticals had a negative net margin of 279.31% and a negative return on equity of 160.60%. The firm’s revenue for the quarter was up 266.4% on a year-over-year basis. During the same period last year, the firm posted ($0.98) EPS. On average, equities research analysts expect that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.